Clinical trials: Liver and Intrahepatic Biliary Tract Cancer
Liver Carcinoma
De Novo Sirolimus-based Immunosuppression After Liver Transplantation for Hepatocellular Carcinoma
This study investigates whether sirolimus could decrease the rate of hepatoma recurrence after liver transplantation in high risk hepatoma patients.
- Trial name
- NCT00328770
- Testing
- Sirolimus
- Where
- Canada
- Volunteers
- 70 people
- Sponsor
- University of Alberta
Liver Cancer
Sirolimus and Bevacizumab in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery
RATIONALE: Sirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways.
- Trial name
- NCT00467194
- Testing
- Rapamycin, Bevacizumab
- Where
- 2 sites in Singapore
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- National Cancer Centre, Singapore
Radiotherapy
Adaptative MR-Guided Stereotactic Body Radiotherapy of Liver Tumors
Hepatic metastases are common in solid cancers (up to 30% of patients with colorectal cancer and up to 50% of patients during their follow-up).
- Trial name
- RASTAF (NCT04242342)
- Testing
- Adaptative MR-Guided Stereotactic Body Radiotherapy
- Where
- France
- Volunteers
- 46 people
- Sponsor
- Centre Georges Francois Leclerc
Hepatocellular Carcinoma Resectable
Drug Sensitivity Testing-Based Tumor Organoids to Guide Adjuvant Therapy After Hepatectomy for Primary Liver Cancer
This is a single-center, prospective, non-randomized, open-label, phase II clinical trial aiming to evaluate the efficacy and feasibility of using patient-derived tumor organoid drug sensitivity testing (ODST) to guide…
- Trial name
- NCT07363356
- Testing
- Organoid Drug Sensitivity Testing-Guided Therapy
- Where
- China
- Volunteers
- 56 people
- Sponsor
- Eastern Hepatobiliary Surgery Hospital
Advanced Hepatocellular Carcinoma (HCC)
Safety and Efficacy of Paclitaxel Liposome Arterial Infusion Combined With Systemic Therapy for Second-Line Treatment of Advanced Liver Cancer
This trial is an open-label, dose-escalation, and randomized controlled Phase Ib/II clinical study for second-line treatment in participants with advanced hepatocellular carcinoma (HCC).
- Trial name
- NCT07282509
- Testing
- HA131, Enlonstobart Injection, Pembrolizumab Injection
- Volunteers
- 116 people
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Liver Cancer
Prospective Liver Study
This study is designed for patients diagnosed with Liver cancer to collect information about the relationship between types of liver cancer, methods of treatment and outcomes over time.
- Trial name
- NCT01539993
- Where
- United States
- Volunteers
- 400 people
- Sponsor
- Emory University
Hepatocellular Carcinoma, Cirrhosis
LDE225 in Patients With Advanced or Metastatic Hepatocellular Carcinoma and Child-Pugh A/B7 Cirrhosis
The purpose of this study is to test the safety and determine the maximum safe dose of an experimental drug called LDE225 (hedgehog inhibitor) in people with liver cancer.
- Trial name
- NCT02151864
- Testing
- LDE225
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Jason K. Sicklick, M.D.
Hepatocellular Carcinoma (HCC)
A Study of TPST-1120 With Atezolizumab Plus Bevacizumab in Patients With Unresectable or Metastatic HCC Not Previously Treated With Systemic Therapy
The goal of this clinical trial is to determine if TPST-1120 in combination with atezolizumab and bevacizumab helps patients to live longer compared to atezolizumab and bevacizumab alone (the standard of care treatment) in adult…
- Trial name
- NCT06680258
- Testing
- TPST-1120, Atezolizumab, Bevacizumab
- Volunteers
- 740 people
- Sponsor
- Tempest Therapeutics
Focal Liver Lesions, Liver Cancer
Characterization of Focal Liver Lesions by Real-time Contrast-enhanced Ultrasound Imaging (CEUS)
The conventional sonography is frequently used to detect incidental focal liver lesions because of its availability, innocuity and low cost.
- Conditions
- Focal Liver Lesions, Liver Cancer, Liver Cirrhosis
- Trial name
- NCT00243633
- Testing
- Real-time contrast-enhanced ultrasound sonography
- Where
- 15 sites in France
- Volunteers
- 878 people
- Sponsor
- University Hospital, Tours
HCC, Liver Cirrhosis
Open Label Trial of Immunotherapy for Advanced Liver Cancer
The purpose of this study is to evaluate daily dosing of oral immunotherapy hepcortespenlisimut-L (V5) in patients with advanced stage of HCC not amenable to surgical intervention or with recurrent tumor after surgery.
- Trial name
- HCC (NCT02256514)
- Testing
- Daily oral dose of hepcortespenlisimut-L
- Where
- Mongolia
- Volunteers
- 120 people
- Sponsor
- Immunitor LLC
Liver Cancer (Primary and Metastatic), Renal Cancer
Intra-procedural Spectral CT for Image-guided Embolization and Ablation in Interventional Oncology
This is a pilot study to evaluate the feasibility, image quality, and procedural utility of a novel spectral CT technique using Canon Medical's 4D CT system during image-guided interventional oncology procedures
- Trial name
- NCT07303725
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Palo Alto Veterans Institute for Research
Brain Tumor, Central Nervous System Tumor
Sodium Thiosulfate in Preventing Hearing Loss in Young Patients Receiving Cisplatin for Newly Diagnosed Germ Cell Tumor, Hepatoblastoma, Medulloblastoma, Neuroblastoma, Osteosarcoma, or Other Malignancy
RATIONALE: Sodium thiosulfate may reduce or prevent hearing loss in young patients receiving cisplatin for cancer. It is not yet known whether sodium thiosulfate is more effective than no additional treatment in preventing…
- Conditions
- Brain Tumor, Central Nervous System Tumor, Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor
- Trial name
- NCT00716976
- Testing
- sodium thiosulfate, examination
- Where
- 76 sites in United States, Australia and 1 more
- Volunteers
- 131 people
- Sponsor
- Children's Oncology Group
Hepatocellular Carcinoma
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma
This is a Phase I study, which means that the goal is to see if the combination of Temsirolimus and Sorafenib is safe in patients with Hepatocellular Carcinoma. Sorafenib is a standard treatment for Hepatocellular Carcinoma.
- Trial name
- NCT01008917
- Testing
- sorafenib with temsirolimus
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- University of California, San Francisco
Liver Cancer, Surgery
HepaT1ca: Quantifying Liver Health in Surgical Candidates for Liver Malignancies
This observational clinical cohort study aims to evaluate the clinical utility of LiverMultiScan in quantifying liver health prior to liver resection or TACE.
- Conditions
- Liver Cancer, Surgery, Liver Regeneration, Colorectal Cancer Metastatic
- Trial name
- Hepatica (NCT03213314)
- Testing
- Multiparameter magnetic resonance imaging
- Where
- 2 sites in United Kingdom
- Volunteers
- 149 people
- Sponsor
- University of Edinburgh
Hepatocellular Carcinoma, Liver Cancer
TheraSphere® for Treatment of Unresectable Hepatocellular Carcinoma
The purpose of this protocol is to provide TheraSphere treatment for patients with liver cancer who cannot be treated by surgery. The effect on the tumor and any side effects of TheraSphere treatment will be examined.
- Conditions
- Hepatocellular Carcinoma, Liver Cancer, Liver Neoplasm, Primary Liver Cancer
- Trial name
- TheraSphere (NCT00906984)
- Testing
- TheraSphere
- Where
- United States
- Sponsor
- University of California, Irvine
Liver Tumor; Surgery, Primary Liver Tumor, Metastatic Liver
Stroke Volume Variation Versus Central Venous Pressure Guidance for Reducing Perioperative Blood Loss During Open Liver Resection, A Non-inferiority Randomized Controlled Trial
Liver resection is a major surgery that can be associated with significant intraoperative blood loss and blood transfusion. Among high-volume centers, median intraoperative blood loss ranges between 300-800 ml.
- Conditions
- Liver Tumor; Surgery, Primary Liver Tumor, Metastatic Liver, Primary Liver Cancer, Liver Resection
- Trial name
- NCT06905015
- Testing
- High SVV-guided fluid management, Low CVP-guided fluid management
- Where
- Thailand
- Volunteers
- 70 people
- Sponsor
- Chiang Mai University
Hepatocellular Carcinoma
Assess Efficacy and Safety of Durvalumab Alone or Combined With Bevacizumab in High Risk of Recurrence HCC Patients After Curative Treatment
A global study to assess the efficacy and safety of durvalumab in combination with bevacizumab or durvalumab alone in patients with hepatocellular carcinoma who are at high risk of recurrence.
- Trial name
- EMERALD-2 (NCT03847428)
- Testing
- Durvalumab, Bevacizumab
- Where
- 217 sites in United States, Australia and 22 more
- Volunteers
- 908 people
- Sponsor
- AstraZeneca
Colorectal Cancer, Liver Cancer
Acupuncture for Oxaliplatin-induced Peripheral Neuropathy in Gastro-intestinal Cancer Patients
ACUPOX is a multicenter, open label, 2-cohort based phase II clinical study evaluating the interest of a standardized protocol of verum acupuncture in treatment of Oxaliplatin-induced peripheral neuropathy in patients with…
- Conditions
- Colorectal Cancer, Liver Cancer, Gastric Cancer, Pancreas Cancer
- Trial name
- ACUPOX (NCT05850130)
- Testing
- Acupuncture intervention, No acupuncture
- Where
- 15 sites in France
- Volunteers
- 182 people
- Sponsor
- GERCOR - Multidisciplinary Oncology Cooperative Group
Unresectable Hepatocellular Carcinoma
Ph 2 Trial of ADI PEG 20 Plus Concurrent Transarterial Chemoembolization (TACE) Vs TACE Alone in Patients With Unresectable Hepatocellular Carcinoma
Certain cancers require the amino acid arginine. Arginine deiminase (ADI) is an enzyme from microbes that degrade arginine. ADI has been formulated with polyethylene glycol and has been used to treat patients that have cancers…
- Trial name
- TACE (NCT02006030)
- Testing
- ADI-PEG 20, Transarterial chemoembolization
- Where
- 4 sites in Taiwan
- Volunteers
- 30 people
- Sponsor
- Polaris Group
Hepatocellular Carcinoma, Cholangiocarcinoma, Intrahepatic
Study of GNS561 in Patients With Liver Cancer
This is a first in human, open-label dose escalation study to investigate the safety, tolerability and pharmacokinetics of GNS561 in patients Primary and Secondary liver cancer
- Trial name
- NCT03316222
- Testing
- GNS561
- Where
- 5 sites in United States, Belgium and 1 more
- Volunteers
- 50 people
- Sponsor
- Genoscience Pharma
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.